Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Stopped early · Phase 2

Conditions studied: Kidney Failure, Chronic

In brief

The purpose of this study is to determine if IGIV-C, 10% will be effective in converting a donor-recipient crossmatch status from positive to negative. The crossmatch test is used to determine if the donor tissue and recipient tissue are compatible. The study will also evaluate if IGIV-C, 10% will allow successful kidney transplantation in a patient who otherwise would not be able to receive a transplant. Three dose levels of IGIV-C, 10% will be evaluated to determine what dose level is most effective.

Key facts

Study ID
NCT00090194
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
56
Starts
2003-06-01
Expected to finish
2004-03-01
Last updated by the study team
2017-01-11

Who can join

Age: 1 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.